Telecoaching program to increase physical activity after lung cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates a 12-week telecoaching program designed to enhance physical activity in patients who have undergone surgery for resectable non-small cell lung cancer (NSCLC). Participants will be randomly assigned to either the intervention group, which receives telecoaching and a wearable device to track their daily steps, or the control group receiving usual care. The study aims to assess the effectiveness and acceptability of this program in improving physical activity levels among patients recovering from lung surgery. The trial will enroll patients from one month to one year post-surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Resectable (I-IIIA) NSCLC patients who had lung resection surgery, one to twelve months before inclusion, with or without (neo-)adjuvant chemotherapy/radiotherapy/immunotherapy.
* If patients received adjuvant chemotherapy/radiotherapy, the inclusion window is one months to twelve months after the end of adjuvant chemotherapy/radiotherapy.
* If patients receive adjuvant immunotherapy after the end of adjuvant chemotherapy, patients can be included during the immunotherapy.
* Adults (18+ year)
* Patients who do not systematically perform structured exercise or are planned to do so.
* Ability to give informed consent

Exclusion Criteria:

* Patients having progressive or recurrent lung cancer
* Patients who had other malignancies in the last 2 years
* Psychiatric disorders that preclude them from participation in a physical activity intervention and/or performing the test battery
* Unable to learn to work with a new electronic device (e.g. smartphone)
* Not understanding and speaking Dutch
* Patients with comorbidities or other treatments that preclude them from participation in a physical activity intervention and/or performing the test battery

Where it's running

• Ziekenhuis Oost-Limburg
  Genk, Limburg, Belgium Recruiting
• Hasselt University
  Hasselt, Limburg, Belgium Recruiting
• Ghent University Hospital
  Ghent, Oost-Vlaanderen, Belgium Recruiting
• AZ Sint-Jan
  Bruges, West-Vlaanderen, Belgium Recruiting
• AZ Delta
  Roeselare, West-Vlaanderen, Belgium Recruiting
• Jessa Ziekenhuis
  Hasselt, Limburg, Belgium Not yet recruiting

Study contacts

• Principal investigator: Dieter Stevens, MD — University Hospital, Ghent
• Study coordinator: Eva Arents, MSc
• Email: eva.arents@ugent.be
• Phone: 003293320528

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing the safety and effects of DO-2 in patients with advanced solid tumors

  This study is testing a new drug called DO-2 to see if it's safe and how it works for people with advanced solid tumors that have specific genetic changes.

  Recruiting at 10 sites Phase 1 DeuterOncology · Brussels and 12 other locations · NCT05752552

• Targeted radiation therapy for advanced lung cancer

  This study is testing if adding a special type of radiation therapy to regular drug treatment can help people with advanced lung cancer that has spread to the liver feel better and live longer.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Miami, Florida and 8 other locations · NCT05657873

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.